About Us
Mission
Leadership
Board of Directors
Science & Pipeline
Technology
Pipeline
Programs
Publications
Patient Community
Unmet Need in LARC
Clinical Trials
Expanded Access
News
About Us
Mission
Leadership
Board of Directors
Science & Pipeline
Technology
Pipeline
Programs
Publications
Patient Community
Unmet Need in LARC
Clinical Trials
Expanded Access
News
News
Year
All Years
2025
2024
2023
Filter
October 14, 2025
Akamis Bio Receives FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer
August 12, 2025
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors
May 6, 2025
Akamis Bio Broadens Leadership Team with Key Executive Appointments
April 3, 2025
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer
December 17, 2024
Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership
October 23, 2024
Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
October 3, 2023
Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer
No results found. Please try different filter selections.
